Princess Dr. Haya bint Khaled bin Bandar Al Saud, Senior Vice President of Research at Hevolution, emphasized that prevention-focused healthcare is no longer optional but essential for global well-being and economic resilience.

Speaking during the launch of the foundation’s second Global Healthspan Report in Riyadh, she highlighted that modern medicine must move beyond responding to illness and instead focus on delaying or preventing disease altogether.

She stressed that this transformation should begin early, particularly in the education and training of healthcare professionals, ensuring that prevention and healthy aging are embedded as core medical priorities.

Equally important, she noted, is raising public awareness so individuals understand that healthspan science directly affects everyone, regardless of geography, income, or background.

The Global Healthspan Report calls for coordinated international action to position healthy aging as both a social responsibility and an economic imperative that supports productivity and sustainable growth.

Healthspan science, which focuses on extending the years people live in good health rather than simply increasing lifespan, is emerging as a defining frontier in global healthcare innovation.

The report identifies five key forces shaping this new era, including rising public awareness, scientific breakthroughs, artificial intelligence and data transformation, growing investment momentum, and urgent economic and policy considerations.

While momentum is building, the findings make clear that progress will require strong leadership and collaboration among scientists, policymakers, investors, and public institutions worldwide.

Princess Dr. Haya underlined that healthspan investments must serve the broader public, ensuring that scientific advancements translate into accessible benefits rather than remaining limited to select populations.

Survey data across 23 countries revealed that awareness of healthspan is rapidly increasing, with two-thirds of healthcare professionals now receiving regular patient inquiries about preventive and longevity-focused interventions.

At the same time, the report highlights growing expectations for government involvement, with 80 percent of citizens believing preventive healthcare programs should be publicly funded.

Concerns about inequality remain, as nearly four in ten respondents expressed worry that access to healthspan innovations may not be evenly distributed across societies.

Artificial intelligence is expected to play a transformative role, with a majority of experts believing it will significantly reshape healthspan research and healthcare delivery in the coming years.

However, ethical concerns and trust gaps persist, particularly around the use of AI in diagnostics, signaling the need for transparent regulation and public engagement.

From an investment perspective, healthspan funding has accelerated rapidly, with global investments more than doubling in recent years as confidence in the field matures.

Investment in healthspan reached more than $7 billion in 2024, reflecting strong belief in its potential to deliver both health outcomes and long-term economic returns.

Hevolution Foundation has positioned itself as a global leader in this space, committing hundreds of millions of dollars to research grants, partnerships, and biotechnology ventures.

According to the report, expanding preventive care and healthspan innovation could generate up to $220 billion annually in productivity gains, with every dollar invested in prevention yielding significant returns.

Founded to extend healthy human lifespan for all, Hevolution continues to advance independent research, entrepreneurship, and global collaboration from its headquarters in Riyadh and its international hubs.

Strong investor interest and rising demand for advanced diagnostic imaging push Lumexa Imaging into the spotlight as one of the year’s most promising healthcare listings.

Lumexa Imaging entered the Nasdaq market with steady momentum as its shares edged upward during the first day of trading, placing the advanced diagnostic imaging provider at a valuation of $1.76 billion and highlighting continued investor appetite for healthcare offerings during an active year for new listings.

The company’s public debut arrives at a moment when the U.S. IPO market is regaining strength, overcoming earlier disruptions and reviving activity after several subdued years marked by economic uncertainty and regulatory delays.

Market analysts note that investor enthusiasm for high-demand healthcare services remains strong, especially in areas linked to demographic shifts, rising chronic disease rates and expanding adoption of advanced diagnostic technologies across medical systems.

Lumexa Imaging’s offering gained early attention as it opened slightly above its initial price, signaling confidence in the company’s business model, revenue stability and long-term expansion strategy across rapidly growing regional markets.

The company, supported by one of the country’s longstanding private equity firms, has built a broad national presence with more than a hundred imaging centers offering MRI, CT and other essential procedures that continue to see rising demand.

Healthcare specialists point out that growth in imaging is accelerating as hospitals and clinics increase their reliance on fast, accurate diagnostic tools that support early detection, personalized care and improved patient outcomes across multiple specialties.

Executives at the company say that the timing of the listing reflects a strategic decision to scale operations, invest in technology and expand access to advanced imaging at a moment when health systems are seeking reliable partners to manage rising diagnostic volumes.

Industry analysts highlight that investor interest is also tied to the company’s strong commitment to integrating artificial intelligence across its workflow, a shift that is reshaping radiology by improving accuracy, speeding up image interpretation and raising overall efficiency.

The company’s leadership emphasized that AI has become essential to modern radiology, enabling clinicians to manage higher caseloads, reduce errors and deliver more consistent results while supporting healthcare networks facing staffing constraints and rising patient expectations.

Lumexa Imaging raised more than four hundred million dollars through the offering, providing fresh capital to enhance network capacity, strengthen technology platforms and pursue further expansion in regions where demand for diagnostic imaging continues to outpace available resources.

As demographic changes accelerate nationwide, the need for imaging has surged, driven by an aging population and increased prevalence of lifestyle-related conditions that require ongoing monitoring and advanced diagnostic evaluation.

The company’s network of centers spans more than a dozen states, offering communities access to essential health services while supporting hospitals, specialty practices and primary care providers with reliable diagnostic capabilities.

Financial strategists say the company’s debut illustrates the broader trend of healthcare organizations turning to public markets to support modernization efforts, particularly in high-demand niches where technology and clinical expertise converge.

Much of the enthusiasm surrounding Lumexa’s debut reflects a belief that diagnostic imaging remains one of the most stable and essential services in the healthcare system, with long-term growth driven by both technological innovation and population needs.

As the company steps into the public arena, industry observers expect continued focus on expanding access, enhancing transparency and integrating next-generation digital tools that advance patient care across the country.

With momentum building for healthcare IPOs and investor interest climbing, Lumexa Imaging’s debut is positioned as an encouraging sign for companies seeking to grow in a rapidly evolving medical landscape defined by innovation, technology and rising patient demand.

Now in its eighth edition, the event has become a cornerstone for the Kingdom’s efforts to attract investment, foster innovation, and advance the strategic goals of Vision 2030.

The exhibition, held with the support of the Ministry of Health, will highlight Saudi Arabia’s commitment to enhancing healthcare quality, boosting the sector’s contribution to the economy, and establishing the Kingdom as a global hub for healthcare innovation and manufacturing.

Over the next decade, the Saudi healthcare industry is projected to grow significantly, from SR199 billion ($53 billion) in 2020 to SR318 billion by 2030, with private sector contributions expected to double to SR145 billion.

The Ministry of Health has emphasized its focus on creating a competitive investment environment, streamlining regulatory processes, and supporting innovation across critical areas such as biotechnology, pharmaceuticals, vaccine production, health tourism, digital health solutions, and artificial intelligence in healthcare.

These initiatives are designed to accelerate progress toward a self-sufficient, innovation-driven healthcare ecosystem in the Kingdom.

The Global Health Exhibition serves as a vital platform for connecting local and international stakeholders, showcasing the latest medical technologies, and facilitating high-value collaborations.

Last year’s edition generated investments exceeding SR50 billion, including key deals such as the SR4 billion pharmaceutical partnership between NUPCO, Novo Nordisk, and Sanofi, the SR5 billion expansion plan by Fakeeh Care Group, and acquisitions worth over SR4 billion by Dallah Healthcare.

Building on this momentum, the 2025 exhibition is expected to announce new agreements and collaborations in biotechnology, advanced medical technologies, AI-driven healthcare solutions, and digital health platforms.

These developments are expected to further strengthen Saudi Arabia’s position as a regional leader in medical innovation, research, and development, attracting global expertise and investment to the Kingdom.

Experts highlight that the exhibition not only provides a showcase for cutting-edge technology and services but also demonstrates the Kingdom’s commitment to Vision 2030 goals of improving healthcare outcomes, supporting economic diversification, and encouraging private sector growth.

By fostering partnerships in pharmaceuticals, biotech, and healthcare technologies, Saudi Arabia aims to reduce dependency on imports, enhance local manufacturing capabilities, and stimulate job creation in high-value sectors.

The Ministry of Health has also emphasized the role of the exhibition in promoting sustainable growth and innovation, particularly in fields like vaccine production, biotechnology research, digital health solutions, and AI-enabled healthcare tools.

These areas are expected to be central to the Kingdom’s long-term strategy of establishing a world-class healthcare ecosystem that combines technological innovation with high-quality patient care.

Stakeholders anticipate that the event will attract international investors, leading global healthcare companies, and innovative startups, creating opportunities for knowledge exchange, joint ventures, and technology transfer.

The exhibition is expected to highlight Saudi Arabia’s readiness to lead in medical research, biotechnology, and advanced healthcare solutions, reinforcing its role as a hub for global healthcare innovation.

As the Kingdom continues to implement initiatives aligned with Vision 2030, the Global Health Exhibition 2025 represents a critical platform for showcasing achievements, facilitating investment, and strengthening partnerships across the healthcare sector.

By leveraging new technologies, fostering collaboration, and expanding strategic partnerships, Saudi Arabia is well-positioned to enhance healthcare access, improve quality, and secure long-term sustainable growth.

In summary, the upcoming exhibition is set to be a landmark event for Saudi Arabia’s healthcare sector, underlining the Kingdom’s dedication to innovation, investment, and international collaboration.

The announcements and partnerships expected at the event will pave the way for a robust, self-sufficient, and technologically advanced healthcare ecosystem, reflecting Saudi Arabia’s ambition to lead in global healthcare innovation.